Wockhardt Ltd. is in Pharmaceuticals & Drugs. It was incorporated in year 1999. The current market capitalisation stands Rs 2728 Cr. The company is listed on the Bombay Stock Exchange (BSE) with the BSE code as 532300. and also listed on National Stock Exchange (NSE) with NSE code as WOCKPHARMA.
Wockhardt Limited, a pharmaceutical and biotechnology company, manufactures and markets active pharmaceutical ingredients (APIs), formulations, bio-similars, and vaccines in India, the United States, Europe, and internationally. It provides pharmaceutical products in the therapeutic areas of anti-infectives, cardiology, dermatology, diabetology, neurology, pain management, respiratory, and other areas. The offers generic products that comprise injectables, including cephalosporins and non-cephalosporins; molecules; and value-added generics. Its biopharmaceutical products include Glaritus, an insulin analog; Wosulin, which is r-DNA insulin; Wepox, a recombinant erythropoietin is used in the treatment of anaemia caused by cancer and chronic renal failure; and Biovac-B, a hepatitis B vaccine. The also provides contract manufacturing services for sterile injectables, lyophilisation, and other dosage forms; API manufacturing services; and research services. It develops various molecules primarily in the area of anti-infectives, which include WCK 771 that is in Phase II human clinical trials for the treatment of staphylococcal infections; and WCK 2349, WCK 4873, and WCK 4086 lead molecules, which are under pre-clinical trials. The was incorporated in 1999 and is headquartered in Mumbai, India. Wockhardt Limited is a subsidiary of Themisto Trustee Private Limited.